Future oncology最新文献

{"title":"Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).","authors":"Carolin Angendohr, Christian Weigel, Anselm Kunstein, Markus Joerdens, Thorsten Goetze, Salah-Eddin Al-Batran, Bianca Zäpf, Maria Gonzalez-Carmona, Cennet Sahin, Marie-Luise Berres, Friedrich Foerster, Najib Ben Khaled, Christine Koch, Arne Kandulski, Henning Wege, Jonel Trebicka, Leonie S Jochheim, Michael T Dill, Christoph Springfeld, Severin Daum, Christoph Treese, Ursula Ehmer, Tom Luedde, Johannes Bode, Christoph Roderburg","doi":"10.1080/14796694.2026.2748246","DOIUrl":"https://doi.org/10.1080/14796694.2026.2748246","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with most patients diagnosed at an advanced stage. Atezolizumab plus bevacizumab is a current standard first-line therapy; however, outcomes are strongly influenced by underlying cirrhosis and clinically significant portal hypertension (CSPH). Complications such as ascites and variceal bleeding may limit treatment continuation, particularly as bevacizumab increases bleeding risk. Transjugular intrahepatic portosystemic shunt (TIPS) reduces portal pressure and may improve outcomes, but its role in patients receiving immunoncology-based systemic therapy remains unclear.</p><p><strong>Methods: </strong>NISTIPS TRITICC-4 is a prospective, multicentre, non-interventional cohort study conducted at up to 25 centers in Germany. A total of 350 adult patients with cirrhosis and unresectable or metastatic HCC receiving first-line atezolizumab plus bevacizumab will be enrolled. Patients are allocated to two cohorts: TIPS in situ plus atezolizumab and bevacizumab or atezolizumab plus bevacizumab alone, according to routine clinical practice.The primary endpoint is time to deterioration of liver function (TTDL), defined as persistent worsening of liver parameters for >4 weeks. Secondary endpoints include overall survival, time on treatment, overall response rate, time to new extrahepatic lesions or death, and safety with focus on bleeding and TIPS-related complications.Time-to-event endpoints will be analyzed using Kaplan-Meier methods and Cox models. Propensity score matching will be applied to adjust for confounding. Analyses are exploratory.</p><p><strong>Discussion: </strong>This study will provide real-world evidence on the impact of TIPS in HCC patients receiving atezolizumab plus bevacizumab and may support more individualized management strategies in this high-risk population.</p><p><strong>Clinical trial registration: </strong>www.clinicaltrials.gov identifier is NCT07365930.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness of first-line chemoimmunotherapy versus chemotherapy in older adults with extensive-stage small cell lung cancer: an inverse probability treatment weighted analysis.","authors":"Siyuan Cui, Kui Zhao, Na Wang, Yuan Meng, Xiaoshan Wang, Chaoran Wang, Fanming Kong","doi":"10.1080/14796694.2026.2750718","DOIUrl":"https://doi.org/10.1080/14796694.2026.2750718","url":null,"abstract":"<p><strong>Aims: </strong>First-line chemoimmunotherapy (ICI-chemo) has become the standard of care for extensive-stage small cell lung cancer (ES-SCLC). However, older adults are underrepresented in pivotal trials due to strict inclusion criteria that limit participation to highly selected, fit patients. Given the limited real-world comparative data, this study aimed to determine whether older adults with ES-SCLC derive greater benefit from ICI-chemo compared with chemotherapy (chemo) alone.</p><p><strong>Patients and methods: </strong>We conducted a single-center retrospective cohort study including ES-SCLC patients aged 65 years or older who started first-line ICI-chemo or chemo between January 2020 and July 2024. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline confounding. The main outcome was overall survival (OS) in the IPTW population.</p><p><strong>Results: </strong>In the IPTW population, median OS was significantly longer in the ICI-chemo group (14.95 months; 95% CI, 12.94-19.91) compared with chemo (10.28 months; 95% CI, 8.11-13.17; HR, 0.66; 95% CI, 0.48-0.91; <i>p</i> = 0.011). Multivariable analysis confirmed that ICI-chemo exposure was independently associated with improved OS (HR, 0.608; 95% CI, 0.440-0.841; <i>p</i> = 0.003).</p><p><strong>Conclusions: </strong>Our findings provide comparative evidence of improved survival in association with ICI-chemo compared with chemo in older adults with ES-SCLC.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-12"},"PeriodicalIF":3.1,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-driven analysis of genomic alterations in colorectal cancer patients.","authors":"Enrique Velazquez-Villarreal","doi":"10.1080/14796694.2026.2751396","DOIUrl":"https://doi.org/10.1080/14796694.2026.2751396","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-4"},"PeriodicalIF":3.1,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line osimertinib with or without chemotherapy for EGFR-mutant advanced NSCLC in China: a cost-effectiveness analysis.","authors":"Guojin Zhou, Jie Chen, Liuxian Guo, Jing Xu","doi":"10.1080/14796694.2026.2750655","DOIUrl":"https://doi.org/10.1080/14796694.2026.2750655","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the cost-effectiveness of adding chemotherapy to first-line osimertinib compared with osimertinib alone among advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations in China.</p><p><strong>Methods: </strong>A partitioned survival model was developed to project lifetime costs and health outcomes. Model inputs included direct medical costs, utility, and clinical parameters. Deterministic and probabilistic sensitivity analyses were conducted to assess parameter uncertainty. The primary outcomes were total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs).</p><p><strong>Results: </strong>Osimertinib plus chemotherapy was associated with higher costs ($62,338.96 vs. $46,929.04) and greater QALYs (3.60 vs. 2.88) than monotherapy, yielding an ICER of $21,410.25 per QALY. Drug costs contributed most to the incremental costs in both arms. Deterministic sensitivity analysis identified the cost of pemetrexed as the most influential parameter. At its highest price, the ICER exceeded the willingness‑to‑pay threshold of $41,876.05 per QALY (three times China's 2025 per capita GDP); otherwise, results remained robust. Probabilistic sensitivity analysis indicated that the combination strategy had a 96.28% probability of being cost-effective. However, these findings should be interpreted with caution, given the extrapolated nature of the survival data.</p><p><strong>Conclusions: </strong>Compared with osimertinib alone, osimertinib plus chemotherapy was likely to be cost-effective as first-line treatment for EGFR-mutated advanced NSCLC in China, but this cost-effectiveness was highly sensitive to the price of pemetrexed.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-8"},"PeriodicalIF":3.1,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer.","authors":"Peter Schmid, Javier Cortes, Rina Hui, Norikazu Masuda, Ana C Garrido-Castro, Delphine Loirat, Zhi-Ming Shao, Yeon Hee Park, Jing Wei, Francisco Beca, Usha Malhotra, Nadia Harbeck","doi":"10.1080/14796694.2026.2732590","DOIUrl":"https://doi.org/10.1080/14796694.2026.2732590","url":null,"abstract":"<p><strong>Clinical trial registration: </strong>NCT06966700 (ClinicalTrials.gov); EU CT 2024-520190-12 (EudraCT).</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.1,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A plain language summary of the 7-year results from the CROWN study: lorlatinib compared with crizotinib in people with ALK-positive non-small cell lung cancer.","authors":"Alice T Shaw, Benjamin J Solomon, Enriqueta Felip, Todd M Bauer, Geoffrey Liu, Yasushi Goto, Yi-Long Wu, Ross A Soo, Julien Mazières, Dong-Wan Kim, Debra Montague, Nancee Pronsati, I-Ming Wang, Jolanda Paolini, Anna Polli, Nada Rifi, Ali Al-Hashimi, Francesca Toffalorio, Tony S K Mok","doi":"10.1080/14796694.2026.2734063","DOIUrl":"https://doi.org/10.1080/14796694.2026.2734063","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-17"},"PeriodicalIF":3.1,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pimicotinib versus placebo in tenosynovial giant cell tumor (TGCT): a plain language summary of the MANEUVER clinical trial.","authors":"Hans Gelderblom, Xiaohui Niu, Silvia Stacchiotti, Sydney Stern, Gabriel Tinoco","doi":"10.1080/14796694.2026.2732810","DOIUrl":"https://doi.org/10.1080/14796694.2026.2732810","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-12"},"PeriodicalIF":3.1,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-6 as a prognostic biomarker in repatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis.","authors":"Yuliya V Perfilyeva, Nurshat Abdolla, Aikyn Kali, Raikhan Tleulieva, Anastassiya V Perfilyeva, Yuriy A Skiba, Yekaterina O Ostapchuk","doi":"10.1080/14796694.2026.2748258","DOIUrl":"https://doi.org/10.1080/14796694.2026.2748258","url":null,"abstract":"<p><strong>Background and aims: </strong>Interleukin-6 (IL-6) has been implicated in the pathogenesis of hepatocellular carcinoma (HCC) and resistance to systemic therapy. This study aimed to evaluate the prognostic value of circulating IL-6 in patients with HCC receiving systemic therapy through a systematic review and meta-analysis.</p><p><strong>Methods: </strong>A systematic literature search was conducted in PubMed, Web of Science, Scopus, and ClinicalTrials.gov from database inception to 27 July 2026. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR).</p><p><strong>Results: </strong>Thirteen studies comprising 1,504 patients were included. Elevated baseline IL-6 was significantly associated with worse OS (hazard ratio [HR] = 2.29, 95%, confidence interval [CI]: 1.87-2.81; <i>p</i> < 0.001), PFS (HR = 1.70, 95% CI: 1.39-2.07; <i>p</i> < 0.001), ORR (odds ratio [OR] = 0.37, 95% CI: 0.23-0.59; <i>p</i> < 0.001), and DCR (OR = 0.39, 95% CI: 0.19-0.78; <i>p</i> = 0.008). Evidence regarding the prognostic value of on-treatment IL-6 concentrations and longitudinal changes during therapy was limited and heterogeneous.</p><p><strong>Conclusions: </strong>High baseline IL-6 is associated with poor prognosis and reduced treatment response in HCC patients receiving systemic therapy, warranting further treatment-specific evaluation of its prognostic utility.</p><p><strong>Protocol registration: </strong>www.crd.york.ac.uk/prospero identifier is CRD420261456976.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-13"},"PeriodicalIF":3.1,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149181030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating taletrectinib in the treatment of patients with <i>ROS1</i> fusion-positive non-small cell lung cancer.","authors":"Misako Nagasaka, Cathleen J Park, Zhaohui L Arter, Torrance Teng, Jacob Lee, Rozhan Ziari, Ravand Samaeekia, Sai-Hong Ignatius Ou","doi":"10.1080/14796694.2026.2740954","DOIUrl":"https://doi.org/10.1080/14796694.2026.2740954","url":null,"abstract":"<p><p><i>ROS1</i> fusion-positive non-small cell lung cancer (NSCLC), occurring in 1-2% of patients, represents a rare but clinically important subset. Patients with <i>ROS1</i> fusion-positive NSCLC are often younger and tend to have little or no history of smoking. Current first-generation tyrosine kinase inhibitors (TKIs) such as crizotinib and entrectinib provide meaningful benefit but are limited by poor central nervous system (CNS) penetration and the development of resistance mutations, particularly <i>G2032R</i>. To overcome the challenges of first‑generation <i>ROS1</i> inhibitors, next‑generation <i>ROS1</i> inhibitors have been developed. Repotrectinib was evaluated earlier, and taletrectinib followed. Both are considered next‑generation <i>ROS1</i> inhibitors with excellent CNS penetration and the ability to tackle resistance mutations such as <i>G2032R,</i> and they have been FDA approved. While both drugs, repotrectinib and taletrectinib, provide impressive results regarding overall and intracranial efficacy, as well as responses seen even in the presence of the resistant <i>G2032R</i> mutation, their toxicity profiles appear different. Repotrectinib appears to have a higher incidence of neurological toxicities, whereas taletrectinib has a higher incidence of gastrointestinal toxicities. Zidesamtinib has recently been approved in the pre-treated population, and taletrectinib is also being evaluated in the adjuvant setting.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-6"},"PeriodicalIF":3.1,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149136345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is IMvigor011 a conventional adjuvant trial or a ctDNA-triggered preemptive treatment strategy?","authors":"Aslı Geçgel, Salih Tünbekici","doi":"10.1080/14796694.2026.2746184","DOIUrl":"https://doi.org/10.1080/14796694.2026.2746184","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-2"},"PeriodicalIF":3.1,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}